DANTROLENE SODIUM FOR INJECTION. Key specifications include physical_form: POWDER, administration: INTRAVENOUS, primary_container_type: VIAL, primary_container_content_quantity: 20.0 MILLIGRAMS OF ACTIVE INGREDIENT, active_medicament_medicinal_strength: 20.000 MILLIGRAMS DANTROLENE SODIUM ACTIVE INGREDIENT. This product is currently in active production with full OEM support.
This part is cataloged in the Federal Logistics Information System (FLIS) under NSN 6505-01-373-2802, indicating validated use in U.S. government and defense logistics supply chains. Available through authorized enterprise resellers and TPM (Third Party Maintenance) channels.
Verify compatibility with your specific system configuration before ordering.
| physical_form | POWDER |
| administration | INTRAVENOUS |
| special_features | CONTAINS 3000 MG MANNITO AND SUFFICIENT SODIUM HYDROXIDE TO YIELD A PH OF APPROX. 9.5; FOR RECONSTITUTION WATER FOR INJECTION WITHOUT BACTERIOSTATIC AGENT; FOR TREATMENT OF MALIGNANT HYPERTHERMIA |
| primary_container_type | VIAL |
| total_primary_container_quantity | 6 |
| primary_container_content_quantity | 20.0 MILLIGRAMS OF ACTIVE INGREDIENT |
| active_medicament_medicinal_strength | 20.000 MILLIGRAMS DANTROLENE SODIUM ACTIVE INGREDIENT |
| NSN | 6505-01-373-2802 |
| ACTIVE MEDICAMENT MEDICINAL STRENGTH | 20.000 MILLIGRAMS DANTROLENE SODIUM ACTIVE INGREDIENT |
| PRIMARY CONTAINER TYPE | VIAL |
| PRIMARY CONTAINER CONTENT QUANTITY | 20.0 MILLIGRAMS OF ACTIVE INGREDIENT |
| PHYSICAL FORM | POWDER |
| ADMINISTRATION | INTRAVENOUS |
| TOTAL PRIMARY CONTAINER QUANTITY | 6 |
| SPECIAL FEATURES | CONTAINS 3000 MG MANNITO AND SUFFICIENT SODIUM HYDROXIDE TO YIELD A PH OF APPROX. 9.5; FOR RECONSTITUTION WATER FOR INJECTION WITHOUT BACTERIOSTATIC AGENT; FOR TREATMENT OF MALIGNANT HYPERTHERMIA |